☰

Nancy Dumont, Ph.D. - Publications

Affiliations: 
2002 Vanderbilt University, Nashville, TN 
Area:
Cell Biology, Oncology, Molecular Biology
Tree Info Grants Similar researchers PubMed Report error

36 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2022 Cervia LD, Shibue T, Borah AA, Gaeta B, He L, Leung L, Li N, Moyer SM, Shim BH, Dumont N, Gonzalez A, Bick NR, Kazachkova M, Dempster JM, Krill-Burger JM, et al. A ubiquitination cascade regulating the integrated stress response and survival in carcinomas. Cancer Discovery. PMID 36576405 DOI: 10.1158/2159-8290.CD-22-1230  0.337
2020 Neggers JE, Paolella BR, Asfaw A, Rothberg MV, Skipper TA, Kalekar RL, Krill-Burger JM, Hong AL, Kugener G, Kalfon J, Yang A, Yuan C, Dumont N, Gonzalez A, Abdusamad M, et al. Abstract LB-053: VPS4A is a synthetic lethal target in VPS4B-deficient cancers due to co-deletion with SMAD4 Cancer Research. 80. DOI: 10.1158/1538-7445.Am2020-Lb-053  0.422
2020 Corsello SM, Spangler RD, Humeidi R, Harrington CN, Nagari RT, Singh R, Wang V, Kocak M, Rossen J, Madec A, Dumont N, Golub TR. Abstract 3400: Adenosine receptor antagonists exhibit potent and selective off-target killing of FOXA1-high cancers Tumor Biology. DOI: 10.1158/1538-7445.Am2020-3400  0.317
2019 Sulahian R, Kwon JJ, Walsh KH, Pailler E, Bosse TL, Thaker M, Almanza D, Dempster JM, Pan J, Piccioni F, Dumont N, Gonzalez A, Rennhack J, Nabet B, Bachman JA, et al. Synthetic Lethal Interaction of SHOC2 Depletion with MEK Inhibition in RAS-Driven Cancers. Cell Reports. 29: 118-134.e8. PMID 31577942 DOI: 10.1016/J.Celrep.2019.08.090  0.367
2019 Chan EM, Shibue T, McFarland JM, Gaeta B, Ghandi M, Dumont N, Gonzalez A, McPartlan JS, Li T, Zhang Y, Bin Liu J, Lazaro JB, Gu P, Piett CG, Apffel A, et al. WRN helicase is a synthetic lethal target in microsatellite unstable cancers. Nature. PMID 30971823 DOI: 10.1038/S41586-019-1102-X  0.329
2019 Kamoun WS, Kirpotin DB, Huang ZR, Tipparaju SK, Noble CO, Hayes ME, Luus L, Koshkaryev A, Kim J, Olivier K, Kornaga T, Oyama S, Askoxylakis V, Pien C, Kuesters G, ... Dumont N, et al. Antitumour activity and tolerability of an EphA2-targeted nanotherapeutic in multiple mouse models. Nature Biomedical Engineering. 3: 264-280. PMID 30952988 DOI: 10.1038/S41551-019-0385-4  0.301
2019 Dumont N, Merrigan S, Turpin J, Lavoie C, Papavasiliou V, Geretti E, Espelin C, Luus L, Kamoun W, Ghasemi O, Sahagian GG, Muller W, Hendriks B, Wickham TJ, Drummond DC. Nanoliposome targeting in breast Cancer is influenced by the tumor microenvironment. Nanomedicine : Nanotechnology, Biology, and Medicine. PMID 30654182 DOI: 10.1016/J.Nano.2018.12.010  0.421
2019 Corsello SM, Spangler RD, Nagari RT, Kocak M, Rossen J, O'Hearn P, Roth J, Gonzalez A, Dumont N, Doench J, Boehm JS, Vazquez F, Tsherniak A, Golub TR. Abstract 2948: Novel cell line barcoding method reveals tepoxalin as a selective drug against MDR1-high tumor cells Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-2948  0.363
2017 Geretti E, Espelin C, Adiwijaya B, Coma S, Koncki Z, Sumner P, Dumont N, Garcia G, Bloom T, Janovsky J, Reynolds J, Campbell K, Moyo V, Molnar I, LoRusso P, et al. Abstract P4-21-40: In vitro and in vivo activity of HER2-targeted antibody-liposomal doxorubicin conjugate MM-302 in HER2-intermediate tumors Cancer Research. 77. DOI: 10.1158/1538-7445.Sabcs16-P4-21-40  0.365
2016 Geretti E, Espelin C, Adiwijaya B, Dumont N, Coma S, Koncki Z, Pham M, Garcia G, Bloom T, Rimkunas V, Reynolds J, Campbell K, Moyo V, Molnar I, LoRusso P, et al. Abstract LB-061: HER2-targeted PEGylated liposomal doxorubicin (MM-302) efficiently targets the HER2 intermediate cell population in vitro and in vivo Cancer Research. 76. DOI: 10.1158/1538-7445.Am2016-Lb-061  0.458
2015 Geretti E, Leonard SC, Dumont N, Lee H, Zheng J, De Souza R, Gaddy DF, Espelin CW, Jaffray DA, Moyo V, Nielsen UB, Wickham TJ, Hendriks BS. Cyclophosphamide-mediated tumor priming for enhanced delivery and anti-tumor activity of HER2-targeted liposomal doxorubicin (MM-302). Molecular Cancer Therapeutics. PMID 26162690 DOI: 10.1158/1535-7163.Mct-15-0314  0.433
2015 Geretti E, Leonard SC, Dumont N, Espelin CW, Gaddy DF, Wickham TJ, Hendriks BS. Abstract P6-11-05: Tumor priming with cyclophosphamide for enhanced tumor delivery, penetration and anti-tumor activity of MM-302, HER2-targeted liposomal doxorubicin Cancer Research. 75. DOI: 10.1158/1538-7445.Sabcs14-P6-11-05  0.44
2015 Dumont N, Geretti E, Leonard SC, Espelin C, Gaddy D, Hendriks B, Nielsen U, Wickham T. Abstract 4134: MM-302 is more effective than PEGylated liposomal doxorubicin (PLD) at reducing pulmonary metastatic burden in breast cancer models expressing intermediate levels of HER2 Cancer Research. 75: 4134-4134. DOI: 10.1158/1538-7445.Am2015-4134  0.448
2013 Roy S, Gascard P, Dumont N, Zhao J, Pan D, Petrie S, Margeta M, Tlsty TD. Rare somatic cells from human breast tissue exhibit extensive lineage plasticity. Proceedings of the National Academy of Sciences of the United States of America. 110: 4598-603. PMID 23487770 DOI: 10.1073/Pnas.1218682110  0.361
2013 Dumont N, Liu B, Defilippis RA, Chang H, Rabban JT, Karnezis AN, Tjoe JA, Marx J, Parvin B, Tlsty TD. Breast fibroblasts modulate early dissemination, tumorigenesis, and metastasis through alteration of extracellular matrix characteristics. Neoplasia (New York, N.Y.). 15: 249-62. PMID 23479504 DOI: 10.1593/Neo.121950  0.442
2013 Roy S, Gascard P, Dumont N, Zhao J, Pan D, Petrie S, Margeta M, Tlsty TD. Abstract LB-273: The tumor suppressor p16INK4a regulates extensive plasticity in rare somatic cells found in adult human tissue. Cancer Research. 73. DOI: 10.1158/1538-7445.Am2013-Lb-273  0.423
2013 Geretti E, Leonard SC, Gaddy DF, Dumont N, Wickham TJ, Hendriks BS. Abstract 3271: Tumor priming with cyclophosphamide increases delivery and activity of Her2-targeted liposomal doxorubicin (MM-302) in preclinical models of breast cancer. Cancer Research. 73: 3271-3271. DOI: 10.1158/1538-7445.Am2013-3271  0.414
2012 DeFilippis RA, Chang H, Dumont N, Rabban JT, Chen YY, Fontenay GV, Berman HK, Gauthier ML, Zhao J, Hu D, Marx JJ, Tjoe JA, Ziv E, Febbraio M, Kerlikowske K, et al. CD36 repression activates a multicellular stromal program shared by high mammographic density and tumor tissues. Cancer Discovery. 2: 826-39. PMID 22777768 DOI: 10.1158/2159-8290.Cd-12-0107  0.363
2011 Drake CR, Miller D, Gascard P, Dumont N, Tseng D, Tisty T, Jones EF. Abstract 5285: Novel antibody-based probes for the detection and study of pre-malignant breast cancer cells Cancer Research. 71: 5285-5285. DOI: 10.1158/1538-7445.Am2011-5285  0.363
2009 Dumont N, Crawford YG, Sigaroudinia M, Nagrani SS, Wilson MB, Buehring GC, Turashvili G, Aparicio S, Gauthier ML, Fordyce CA, McDermott KM, Tlsty TD. Human mammary cancer progression model recapitulates methylation events associated with breast premalignancy. Breast Cancer Research : Bcr. 11: R87. PMID 19995452 DOI: 10.1186/Bcr2457  0.422
2008 Dumont N, Wilson MB, Crawford YG, Reynolds PA, Sigaroudinia M, Tlsty TD. Sustained induction of epithelial to mesenchymal transition activates DNA methylation of genes silenced in basal-like breast cancers. Proceedings of the National Academy of Sciences of the United States of America. 105: 14867-72. PMID 18806226 DOI: 10.1073/Pnas.0807146105  0.404
2008 Criswell TL, Dumont N, Barnett JV, Arteaga CL. Knockdown of the transforming growth factor-beta type III receptor impairs motility and invasion of metastatic cancer cells. Cancer Research. 68: 7304-12. PMID 18794117 DOI: 10.1158/0008-5472.Can-07-6777  0.634
2008 Dumont N, Crawford YG, Reynolds PA, Wilson MB, Sigaroudinia M, Gauthier ML, Fordyce CA, Tlsty TD. Abstract LB-334: Signals from the microenvironment induce a malignant program accompanied by de novo epigenetic remodeling Cancer Research. 68. DOI: 10.1158/1538-7445.Am2008-Lb-334  0.408
2005 Muraoka-Cook RS, Dumont N, Arteaga CL. Dual role of transforming growth factor beta in mammary tumorigenesis and metastatic progression. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 11: 937s-43s. PMID 15701890  0.59
2005 Dumont N, Crawford Y, Reynolds P, Tlsty T. Cooperation between extracellular signaling and intracellular Ras activation leads to immortalization and epithelial-to-mesenchymal transition of variant human mammary epithelial cells Breast Cancer Research. 7: 1-1. DOI: 10.1186/Bcr1126  0.399
2004 Ueda Y, Wang S, Dumont N, Yi JY, Koh Y, Arteaga CL. Overexpression of HER2 (erbB2) in human breast epithelial cells unmasks transforming growth factor beta-induced cell motility. The Journal of Biological Chemistry. 279: 24505-13. PMID 15044465 DOI: 10.1074/Jbc.M400081200  0.603
2004 Bhowmick NA, Chytil A, Plieth D, Gorska AE, Dumont N, Shappell S, Washington MK, Neilson EG, Moses HL. TGF-beta signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. Science (New York, N.Y.). 303: 848-51. PMID 14764882 DOI: 10.1126/Science.1090922  0.492
2003 Dumont N, Arteaga CL. Targeting the TGF beta signaling network in human neoplasia. Cancer Cell. 3: 531-6. PMID 12842082 DOI: 10.1016/S1535-6108(03)00135-1  0.435
2003 Dumont N, Arteaga CL. A kinase-inactive type II TGFbeta receptor impairs BMP signaling in human breast cancer cells. Biochemical and Biophysical Research Communications. 301: 108-12. PMID 12535648 DOI: 10.1016/S0006-291X(02)02977-7  0.538
2003 Dumont N, Bakin AV, Arteaga CL. Autocrine transforming growth factor-beta signaling mediates Smad-independent motility in human cancer cells. The Journal of Biological Chemistry. 278: 3275-85. PMID 12421823 DOI: 10.1074/Jbc.M204623200  0.605
2002 Dumont N, Arteaga CL. The tumor microenvironment: a potential arbitrator of the tumor suppressive and promoting actions of TGFbeta. Differentiation; Research in Biological Diversity. 70: 574-82. PMID 12492498 DOI: 10.1046/J.1432-0436.2002.700910.X  0.559
2002 Law BK, Chytil A, Dumont N, Hamilton EG, Waltner-Law ME, Aakre ME, Covington C, Moses HL. Rapamycin potentiates transforming growth factor beta-induced growth arrest in nontransformed, oncogene-transformed, and human cancer cells. Molecular and Cellular Biology. 22: 8184-98. PMID 12417722 DOI: 10.1128/Mcb.22.23.8184-8198.2002  0.501
2002 Muraoka RS, Dumont N, Ritter CA, Dugger TC, Brantley DM, Chen J, Easterly E, Roebuck LR, Ryan S, Gotwals PJ, Koteliansky V, Arteaga CL. Blockade of TGF-beta inhibits mammary tumor cell viability, migration, and metastases. The Journal of Clinical Investigation. 109: 1551-9. PMID 12070302 DOI: 10.1172/Jci15234  0.631
2001 McEarchern JA, Kobie JJ, Mack V, Wu RS, Meade-Tollin L, Arteaga CL, Dumont N, Besselsen D, Seftor E, Hendrix MJ, Katsanis E, Akporiaye ET. Invasion and metastasis of a mammary tumor involves TGF-beta signaling. International Journal of Cancer. 91: 76-82. PMID 11149423 DOI: 10.1002/1097-0215(20010101)91:1<76::Aid-Ijc1012>3.0.Co;2-8  0.598
2000 Dumont N, Arteaga CL. Transforming growth factor-beta and breast cancer: Tumor promoting effects of transforming growth factor-beta. Breast Cancer Research : Bcr. 2: 125-32. PMID 11250702 DOI: 10.1186/Bcr44  0.642
1999 Dumont N. Genetic and epigenetic contributions to colorectal cancer. Apmis. 107: 711-722. PMID 10515122 DOI: 10.1111/J.1699-0463.1999.Tb01466.X  0.397
Show low-probability matches.